Siteman Cancer Center Starts Offering Novel Cell-Based Immunotherapy Against Melanoma
Patients with melanoma may soon be able to access a new immunotherapy that was recently approved by the U.S. Food and Drug Administration (FDA). The cell-based treatment, which was developed by Iovance Therapeutics, will first be administered by physicians at the Siteman Cancer Center in Washington University before it can be commercialized under the name Amtagvi. The tumor-infiltrating lymphocyte immunotherapy has been designed for the treatment of metastatic melanoma, which is a skin cancer that has spread to other parts of the body. The treatment, called lifileucel, has been designed specifically for patients suffering from this particular cancer whose tumor…
